10 Oversold Stocks to Buy in 2025 Amid Inflation Fears

5. Viatris Inc. (NASDAQ:VTRS)

Viatris Inc. is a healthcare company that operates in Greater China, Emerging Markets, Developed Markets, and JANZ segments. It provides generic drugs, biosimilars, prescription brand drugs, and complex generic drugs. The company’s stock is experiencing a downturn, falling 26% this year.

Drug stocks are under pressure this year due to Donald Trump’s criticism of companies operating from outside the US. While the US follows strict regulatory standards when it comes to drug manufacturing even outside the country,  there is an over-reliance on other countries, which the US admin doesn’t like, especially in the scenario where a war breaks out.

Apart from the above, Viatris has business headwinds it needs to deal with. While Europe is expected to show strong growth in 2025, the same can’t be said about North America, which continues to face pressure from competitors. It plans to continue its dividend policy and add $500 to $600 million in share buybacks, but investors need to see business improvements before they can take comfort in the payouts.